SYGNIS completes X-Pol Biotech acquisition

10-Dec-2012 - Germany

SYGNIS Pharma AG announced that the merger with X-Pol Biotech S.L. (X-Pol) is completed. With the approval of the Annual General Meeting on October 17, 2012 SYGNIS acquired 100% of the shares of the Spanish X-Pol by way of a capital increase against contribution in kind.

Thus X-Pol becomes a 100% subsidiary of SYGNIS and SYGNIS’ share capital is increased from € 2,103,688 to € 9,349,724. After this transaction, the former shareholders of X-Pol hold 77.5% of SYGNIS shares. The previous shareholders of SYGNIS now own 22.5% of the new company. No shares were sold in the capital market.


Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...